Javier Afonso

Among men with locally advanced prostate cancer, transdermal estradiol was noninferior to LHRH agonists for 3-year metastasis-free survival and led to a lower incidence of hot flashes but a higher incidence of gynecomastia. Full results of the STAMPEDE-1 and PATCH trials: nejm.org/doi/full/10.10…

⚡️ New SITC clinical practice guideline (v3.0) on immunotherapy in RCC: practical recommendations across adjuvant + metastatic settings, special populations, response monitoring, and QoL. Key reminders: PD-L1/TMB/MSI don’t guide selection; sarcomatoid features favor IO—nivo/ipi remains a preferred option. #KidneyCancer #RCC @crisbergerot @OncoAlert jitc.bmj.com/content/14/3/e…

Diagnostic Value of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Staging Histological Subtypes of Invasive Bladder Cancer by Renee A.G. Lijnen et al Read the article: buff.ly/wjGnWUU We thank the authors for trusting #EUO with your work. @LAUrology_NL @TBoellaard @FraClaps @uroweb @mroupret @GPloussard @jteoh_hk @Ric_Campi @CaPsurvivorship @UroDocAsh @LauraMarandino @RenuEapen @Ecastromarcos @OncoAlert @Sciencedirect

⚡️ IMDC real-world (n=1,551) metastatic non–clear cell RCC: 1L IO+VE, IO-IO or cabozantinib showed higher ORR and longer OS vs sunitinib/pazopanib or mTOR—but the benefit varies by histology. Papillary: ORR 31–37% & OS ~31–33 mo with contemporary regimens vs 13% & 17.2 mo (SUN/PAZ). Sarcomatoid: IO-IO had the best outcomes (ORR 39%, OS 31.9 mo). #KidneyCancer #RCC sciencedirect.com/science/articl…

🤓 One of our MOST READ ARTICLES (last 30 days)! Prognosis and Treatment Response in Aggressive-variant Prostate Cancer and Treatment-related Neuroendocrine Prostate Cancer: A Systematic Review and Meta-analysis by Martino Pedrani Full article: buff.ly/k3P3S3C We thank the authors for trusting #EUO with your important work! @PedraniMartino @Silke_Gillessen @uroweb @mroupret @GPloussard @jteoh_hk @Ric_Campi @CaPsurvivorship @UroDocAsh @LauraMarandino @RenuEapen @Ecastromarcos @OncoAlert @Sciencedirect

Oncology 2026 WBC Growth Factors: ASCO Guideline Update ascopubs.org/doi/10.1200/JC…

PEACE Program explained 👇 • A European prostate cancer trial platform • Tests escalation at every disease stage • PEACE-1 → Escalation improved survival • PEACE-2 → No benefit, more toxicity • PEACE-3 → OS benefit in bone-predominant mCRPC #ProstateCancer #ASCOGU #MVOnco

KN-B15/EV303: R3 Perioperative EVP vs Gem/cis in MIBC shows EFS HR 0.53 (0.41–0.70), OS HR 0.65 (0.48-0.89), pCR 56% vs 33%, G3+ tox 76% vs 67% #GU26. About half the patients completed 9 cycles of EVP. These are great results. Gem/cid is harder to beat when not all patients are at risk of relapse. Bladder sparing approaches for cCR (~60%) will be where this ends. ‘EVP 1st, ask questions later’. These studies are needed soon.

Here it is the long awaited KEYNOTE -B15/EV-304. A new reference for the perioperative management of MIBC. The combination of enfortumab vedotin + Pembrolizumab improves survival in this settings. Huge congrats to the team brilliantly led by #MattGalsky. Huge congrats also to the senior author @Uro_Oncologist . Clinically significant impact on pCRs, EFS and OS. Now it’s time to digest the data and compare the outcomes with NIAGARA and discuss the expectations created by EV-303

Kidney cancer ≠ one disease. • Clear cell – angiogenesis driven • Papillary – MET driven • Chromophobe – metabolic/mTOR • Translocation – TFE3 fusion • Collecting duct – chemo sensitive Sarcomatoid isn’t a separate type—it can occur in any subtype. #RCC #Oncology #MVOnco

• Surgery alone → ~50% relapse • MVAC → survival breakthrough • GC → better tolerability • ddMVAC → superior 5-yr OS (VESPER) • NIAGARA → chemo + IO improves OS • EV + Pembro → platinum-free era? #BladderCancer #GUOncology #ASCOGU #Immunotherapy #MVOnco

Los medios están perdiendo interés en Irán. Los políticos están perdiendo interés en Irán. Las celebridades y los influencers nunca han mostrado interés por Irán . No lo permitamos. 90 millones de iraníes sufren la mayor matanza del siglo y están aislados del mundo. ¡Sé su voz!

🚨| URGENTE: El Times revela la terrible verdad: 16.500 manifestantes muertos y 330.000 heridos en Irán 🇮🇷. Dos semanas de protestas en Irán han causado más muertes civiles que dos años de guerra en Gaza. Sin embargo, el mundo parece la otra guerra,

Comparison of prostate-specific antigen kinetics between androgen receptor signaling inhibitor doublet therapy and androgen receptor signaling inhibitor with docetaxel triplet therapy in patients with metastatic castration-sensitive #ProstateCancer sciencedirect.com/science/articl… Retrospective real-world study compared doublet versus triplet therapy in patients with metastatic castration-sensitive prostate cancer. After matching, triplet therapy led to a higher rate of deep PSA suppression (≤ 0.02 ng/ml) at 12 months, especially in those with high-volume disease, while early PSA response rates were similar between groups. However, triplet therapy was associated with more frequent severe treatment-related adverse events. Overall, triplet therapy may offer greater PSA benefit for selected patients but with increased toxicity. @OncoAlert 🚨 @silkegillessen @AOmlin @weoncologists

Physical activity decreases cancer burden by alleviating immunosenescence-related inflammation and improving overall immunity x.com/erictopol/stat… ⁦@OncoAlert⁩

Juan No, médico rehabilitador: «Mi mayor ilusión es que un paciente de cáncer me diga que sigue haciendo ejercicio» @somosLVSalud lavoz.gal/f8m1t3

Prostate Cancer Genetics 🧬🔥 What drives advanced mCRPC? #GlobalForum25 #PROSCA25 AR pathway dominates, PTEN loss and PI3K-AKT next, then DDR defects, Rb loss, and TP53 mutations. These are the major therapeutic and prognostic signals. And the ARPi + PARPi story is crystal clear BRCA patients do the best, HRR moderate, non-HRR lowest benefit. Same pattern across PROPEL, TALAPRO-2, MAGNITUDE. The biggest wins always in BRCA1/2. #OncoTwitter #MedTwitter #ProstateCancer @oncoalert @asco @myesmo @esmo_open @mirrorsmed

Before ordering HRR testing, ask this: which method will actually find the mutation? #GlobalForum25 #PROSCA25 🩸 Germline Easy access, stable panels, picks up only 20-50 percent of HRR mutations. Most variants inherited >80 percent. gBRCA2 yield about 2-3.5 percent. 🧫 Somatic tissue Best reflects alterations at biopsy time but technique dependent. FFPE issues and filtering can miss variants. sBRCA2 detection 3-8 percent, turnaround 3-10 weeks. 🧪 Plasma (ctDNA) Similar workflow to somatic but needs adequate tumour fraction. CHIP can confuse interpretation. sBRCA2 yield 3-5 percent, turnaround 3-6 weeks. Takeaway: each method gives different outputs, so test selection matters in mCRPC decision-making 💡 #OncoTwitter #MedTwitter #ProstateCancer @OncoAlert @ASCO @myESMO @ESMO_Open @mirrorsmed

Doublet vs Triplet in mHSPC: Fast Takeaways 🔍 #GlobalForum25 #PROSCA25 🧬 ADT + ARPI = SOC Intensify only when biology or volume demands it. 💥 Doublet enough 😊 Metachronous low volume 😊 Elderly low volume 😊 Low risk biology 👉 ADT + ARPI 🔥 Biology driven intensification 🚨 TP53 or RB1 loss 🚨 PTEN loss 🚨 BRCA or HRR mutations 👉 Add docetaxel 💜 Clear Triplet candidates ⚡ De novo high volume ⚡ AR independent or high proliferative biology 👉 Triplet gives strongest OS effect 🌫️ Avoid intensification 🧓 Frail or comorbid 👉 ADT alone or ARPI if tolerated New Triplets 🆕 🟦 AMPLITUDE: Niraparib 🟩 CAPItello: Capivasertib 🟧 PSMAddition: LuPSMA Different biology, different triplet. #OncoTwitter #MedTwitter #ProstateCancer #mHSPC @oncoalert @asco @myesmo @esmo_open @mirrorsmed